Report cover image

North America Ophthalmic Drugs Market Forecast 2023-2032

Publisher Inkwood Research
Published Nov 17, 2023
Length 161 Pages
SKU # INKR18381622

Description

North America Ophthalmic Drugs Market Forecast 2023-2032



KEY FINDINGS

The North America ophthalmic drugs market is projected to record a CAGR of 5.56% during the forecast period, 2023-2032. Growing awareness of eye health and the accessibility of eye care services are fostering early detection and treatment of eye conditions. This pattern is fueling the expansion of the ophthalmic drugs market in North America.

MARKET INSIGHTS

Canada and the United States are evaluated for the North America ophthalmic drugs market growth assessment. The surge in eye diseases, particularly those associated with aging and lifestyle, is fueling the need for ophthalmic drugs. Progress in drug delivery technologies is amplifying drug effectiveness and patient adherence, contributing to market expansion. With an increasing elderly population in the United States, there is a heightened vulnerability to age-related eye conditions, driving up the demand for ophthalmic drugs. The pharmaceutical industry's dedication to research and development is yielding the creation of advanced ophthalmic drugs, marking a significant stride forward.

The ophthalmic drugs market in the United States is dominated by key players such as Novartis AG, Allergan (now a part of AbbVie Inc), Regeneron Pharmaceuticals, Santen Pharmaceutical Co Ltd, and Bausch Health Companies Inc. These industry leaders consistently invest in research and development, aiming to introduce novel and advanced ophthalmic drugs to the market. This ongoing commitment plays a pivotal role in fostering the growth and progression of eye care in the United States.

COMPETITIVE INSIGHTS

Some of the leading players in the North America ophthalmic drugs market include Bausch Health Companies Inc, Pfizer Inc, AbbVie Inc, etc.

Our report offerings include:
  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


      • Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

161 Pages
1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On Ophthalmic Drugs Market
2.5. Major Market Findings
2.5.1. Emerging Therapies For Dry Eye Syndrome
2.5.2. Growing Demand For Combination Therapies
2.5.3. Increasing Investment In Research & Development
2.5.4. Shift Toward Over-the-counter (Otc) Products
3. Market Dynamics
3.1. Key Drivers
3.1.1. Aging Population’s Susceptibility To Age-related Eye Conditions
3.1.2. Advancements In Drug Delivery Technologies
3.1.3. Rising Prevalence Of Eye Diseases And Disorders
3.1.4. Favorable Reimbursement Policies By Healthcare Systems
3.2. Key Restraints
3.2.1. Delay In Drug Approvals
3.2.2. Side Effects Related To Ophthalmic Drugs
4. Key Analytics
4.1. Key Market Trends
4.2. Technology Snapshot
4.2.1. Biologics
4.2.2. Cell Therapy
4.2.3. Gene Therapy
4.2.4. Drug Delivery
4.2.5. Small Molecule
4.2.6. Other Technologies
4.3. Porter's Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Growth Prospect Mapping
4.5. Market Maturity Analysis
4.6. Market Concentration Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework
5. Market By Indication
5.1. Dry Eye
5.2. Glaucoma
5.3. Infection/Inflammation/Allergies
5.4. Retinal Disorder
5.4.1. Wet Age-related Macular Degeneration
5.4.2. Dry Age-related Macular Degeneration
5.4.3. Diabetic Retinopathy
5.4.4. Other Retinal Disorders
5.5. Other Indications
6. Market By Type
6.1. Prescription Drugs
6.2. Over-the-counter Drugs
7. Market By Dosage Form
7.1. Gels
7.2. Eye Solutions & Suspensions
7.3. Capsules & Tablets
7.4. Eye Drops
7.5. Ointments
8. Market By Therapeutic Class
8.1. Anti-glaucoma
8.2. Anti-infection
8.3. Anti-inflammatory
8.4. Anti-allergy
8.5. Other Therapeutic Classes
9. Market By Distribution Channel
9.1. Hospital Pharmacies
9.2. Drug Stores
9.3. Online Pharmacies
9.4. Other Distribution Channels
10. Geographical Analysis
10.1. North America
10.1.1. Market Size & Estimates
10.1.2. North America Ophthalmic Drugs Market Drivers
10.1.3. North America Ophthalmic Drugs Market Challenges
10.1.4. Key Players In North America Ophthalmic Drugs Market
10.1.5. Country Analysis
10.1.5.1. United States
10.1.5.1.1. United States Ophthalmic Drugs Market Size & Opportunities
10.1.5.2. Canada
10.1.5.2.1. Canada Ophthalmic Drugs Market Size & Opportunities
11. Competitive Landscape
11.1. Key Strategic Developments
11.1.1. Mergers & Acquisitions
11.1.2. Product Launches & Developments
11.1.3. Partnerships & Agreements
11.2. Company Profiles
11.2.1. Abbvie Inc
11.2.1.1. Company Overview
11.2.1.2. Products & Services
11.2.1.3. Strengths & Challenges
11.2.2. Accutome Inc
11.2.2.1. Company Overview
11.2.2.2. Products & Services
11.2.2.3. Strengths & Challenges
11.2.3. Bausch Health Companies Inc
11.2.3.1. Company Overview
11.2.3.2. Products & Services
11.2.3.3. Strengths & Challenges
11.2.4. Genentech Inc
11.2.4.1. Company Overview
11.2.4.2. Products & Services
11.2.4.3. Strengths & Challenges
11.2.5. Johnson & Johnson
11.2.5.1. Company Overview
11.2.5.2. Products & Services
11.2.5.3. Strengths & Challenges
11.2.6. Thea Pharma Inc
11.2.6.1. Company Overview
11.2.6.2. Products & Services
11.2.6.3. Strengths & Challenges
11.2.7. Novartis Ag
11.2.7.1. Company Overview
11.2.7.2. Products & Services
11.2.7.3. Strengths & Challenges
11.2.8. Pfizer Inc
11.2.8.1. Company Overview
11.2.8.2. Products & Services
11.2.8.3. Strengths & Challenges
11.2.9. Regeneron Pharmaceuticals Inc
11.2.9.1. Company Overview
11.2.9.2. Products & Services
11.2.9.3. Strengths & Challenges
11.2.10. Santen Pharmaceutical Co Ltd
11.2.10.1. Company Overview
11.2.10.2. Products & Services
11.2.10.3. Strengths & Challenges
11.2.11. Sun Pharmaceutical Industries Ltd
11.2.11.1. Company Overview
11.2.11.2. Products & Services
11.2.11.3. Strengths & Challenges
11.2.12. Teva Pharmaceuticals Industries Ltd
11.2.12.1. Company Overview
11.2.12.2. Products & Services
11.2.12.3. Strengths & Challenges

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us